Literature DB >> 11590532

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11590532     DOI： 10.1310/RWG0-49RM-GQH4-5BB3

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN： 1528-4336


× No keyword cloud information.
  11 in total

1.  The role of medical and social history in addressing relative contraindications to antiretroviral medications.

Authors:  Mm Kabue; Jm Risser; Rm Grimes
Journal:  Malawi Med J       Date:  2007-06       Impact factor: 0.875

2.  Antiretroviral treatment 2010: progress and controversies.

Authors:  Roy M Gulick
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

Review 3.  Systematic Review of Clinical Practice Guidelines for the Improvement of Medication Adherence.

Authors:  Todd M Ruppar; Fabienne Dobbels; Pawel Lewek; Michal Matyjaszczyk; Kaat Siebens; Sabina M De Geest
Journal:  Int J Behav Med       Date:  2015-12

4.  Correlates of retention in HIV care after release from jail: results from a multi-site study.

Authors:  Amy L Althoff; Alexei Zelenev; Jaimie P Meyer; Jeannia Fu; Shan-Estelle Brown; Panagiotis Vagenas; Ann K Avery; Jacqueline Cruzado-Quiñones; Anne C Spaulding; Frederick L Altice
Journal:  AIDS Behav       Date:  2013-10

5.  Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults.

Authors:  B R Schackman; S J Goldie; M C Weinstein; E Losina; H Zhang; K A Freedberg
Journal:  Am J Public Health       Date:  2001-09       Impact factor: 9.308

6.  Closing the Gap in Antiretroviral Initiation and Viral Suppression: Time Trends and Racial Disparities.

Authors:  Charles F Haines; John A Fleishman; Baligh R Yehia; Bryan Lau; Stephen A Berry; Allison L Agwu; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

7.  Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.

Authors:  Annette Oxenius; Angela R McLean; Marek Fischer; David A Price; Sarah J Dawson; Roland Hafner; Christine Schneider; Helen Joller; Bernard Hirschel; Rodney E Phillips; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 8.  Treatment Options for HIV-Associated Tuberculosis.

Authors:  Philip Chukwuka Onyebujoh; Isabela Ribeiro; Christopher Curtis Whalen
Journal:  J Infect Dis       Date:  2007-08-15       Impact factor: 5.226

9.  Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report.

Authors:  Deniz Gökengin; Tansu Yamazhan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2002-09-16       Impact factor: 3.944

10.  Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease.

Authors:  Jim Shahriar; Thomas Delate; Ron D Hays; Stephen Joel Coons
Journal:  Health Qual Life Outcomes       Date:  2003-07-09       Impact factor: 3.186
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.